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Summary As in many areas of health care, treatmentsforcancer may differonly moderately in theireffects on majorend points, such as death.
But, such differences are worth knowing about, particularly in common diseases in which they could represent a substantial benefit to public
health. Large-scale randomized evidence allows moderate differences to be investigated reliably, and one way to achieve this is by meta-
analyses of updated and centrally collected individual patient data from all relevant trials. This paper illustrates why this form of research can
often be important in cancer. It also offers the first list of such projects, as a source of information on current and past research in this area.
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The conduct of meta-analyses of updated and centrally collected
individual patient data (IPD) from all relevant randomized
controlled trials has been discussed previously (Stewart and
Clarke, 1995). This paper illustrates why this form of research is
often particularly important in cancer. It also publishes the first list
ofIPD meta-analyses in cancer (see Appendix), thereby providing
an important source of information on what research has been, or
is being, conducted in this area. It may also help avoid duplication
of effort as IPD meta-analyses generally involve considerable
work, particularly for those who organize them.
THE NEED FOR SYSTEMATIC REVIEWS TO
ASSESS TREATMENTS FOR CANCER
As in many areas of health care, a fundamental principle under-
lying the need for large-scale randomized evidence in cancer is
that, for major end points, the difference between the treatments
under investigation is unlikely to be large. But, if a widely practi-
cable treatment produced a moderate improvement for a common
disease, this could represent a substantial benefit to public health.
Similarly, clear and reliable evidence that there is no such differ-
ence could avoid much unnecessary treatment, along with its asso-
ciated toxicity and cost (Collins et al, 1996).
Large-scale randomized evidence can be obtained by suitably
large randomized controlled trials (RCTs) that will accrue future
patients, systematic reviews ofpast trials or ideally a combination
ofthe two. At present, most trials in cancer are oflimited size and
so this disease is particularly well suited to systematic review. In
addition, some treatments have been investigated in numerous
RCTs over many years. For example, more than 40 000 women
world-wide have, since 1974, been randomized into at least 50
separate trials of tamoxifen vs no tamoxifen for operable breast
cancer. Data from approximately 30 000 women in 40 ofthe trials
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thatbegan before 1985 were collected and reanalysed by the Early
Breast Cancer Trialists' Collaborative Group (EBCTCG) in 1992
to reveal a small, but highly significant, reduction in 10-year
mortality for women allocated to tamoxifen (EBCTCG, 1992).
INDIVIDUAL PATIENT DATA-BASED
META-ANALYSES: WHAT ARE THEY?
This and the other meta-analyses conducted by the EBCTCG and
other groups listed in the Appendix are based on individual patient
data, in which the separate trial results used in the meta-analysis
come fromcentralanalysis ofthe raw datafrom each trial. Alimited
amount ofinformation on each patient entered into each RCT must
be collected centrally, usually by a small secretariat. Any apparent
inconsistencies or problems are discussed and, hopefully, resolved
by communication with the responsible trialists (Stewart and
Clarke, 1995). The finalized data for each trial are then analysed
separately to obtain summary statistics that are then combined to
give an overall estimate of the effect of treatment. In this way,
patients are compared directly only with others in the same trial.
This paper concentrates on IPD meta-analyses in cancer and a
list ofthese has been prepared (see Appendix). IPD meta-analyses
have also been performed in other areas of health care, such as
antiplatelet therapies in vascular disease (Antiplatelet Trialists'
Collaboration, 1994), methotrexate in rheumatoid arthritis
(Chemoff et al, 1995) and the effects ofexercise in reducing falls
and frailty in the elderly (Province et al, 1995). However, reviews
based on individual patient data are comparatively rare. Thus, the
Cochrane Database of Systematic Reviews (1998), which has
existed for some years, is based mainly on published data and only
recently has it become possible to incorporate individual patient
data. The Appendix does not aim to include any meta-analyses that
have been performed with eitherpublished data alone oraggregate
data suppliedby trialists, examples ofwhich go back more than 20
years (Stjemsward, 1974). However, the authors would welcome
information on any IPD meta-analyses that have been overlooked
and can supply fuller details ofthose included.
The IPD meta-analyses listed in the Appendix are chiefly
concemed with the effects of treatment on relapse or survival
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rather than factors such as quality of life. Some work has been
carried out to combine the results of an IPD meta-analysis of
recurrence and survival with average toxicity information from
other sources to obtain a clearer idea of the influence of different
treatments on a patient's quality of life (Gelber et al, 1996) but, in
general, quality of life has not been measured in many trials and,
when it has been measured, it is likely to prove difficult to
combine the different measures used.
THE ADVANTAGES OF SYSTEMATIC REVIEWS
BASED ON INDIVIDUAL PATIENT DATA TO
ASSESS TREATMENTS FOR CANCER
Among the advantages of using IPD in any systematic review are
that analyses can include time-to-event calculations; consistently
defined patient subgroup and outcome analyses can be performed;
and standardized checking and correction procedures can be
followed for the data from each trial. It might also be easier for
reviewers to obtain additional or updated information on indi-
vidual patients. These advantages should be true for all forms of
health care that can be subjected to systematic review but their
relative importance will, of course, vary. Examples of how they
have applied in IPD meta-analyses of treatments for cancer are
given below.
Time to event analyses
This major advantage of collecting IPD can be obtained even ifan
absolute minimum amount of data is collected, namely the allo-
cated treatment and the time interval to the outcome under investi-
gation. Typically, more data than these are sought on each
randomized patient, but even this minimum would allow summary
statistics based on the entire survival experience to be calculated
and a survival curve to be constructed. In cancer trials and
reviews, the primary outcome of interest is often death and so
these analyses may reveal an important prolongation of survival,
which might not be apparent if follow-up data for a fixed point in
time were collected.
For example, the IPD that were collected for a meta-analysis of
platinum-based combination chemotherapy vs single non-plat-
inum drugs in the treatment of advanced ovarian cancer showed
that a reliance on 2-year survival data would exaggerate the differ-
ence between the two treatments. As Table 1 shows, the improve-
ments in survival for patients allocated to combination
chemotherapy compared with those allocated to a single drug are
clearly at their greatest at 2 years and subsequently there is little
difference between the two treatments (Stewart and Parmar, 1993).
Aggregate data could, of course, be requested from each trial for
each time point to perform these analyses, but this approach will
give less sensitive results, especially when the event rate is high.
Consistency of effect in patient subgroups
In small trials and reviews, subgroup or multiple outcome analyses
may lead to misleading conclusions but if large-scale randomized
evidence is available then this can be used, with appropriate
caution, in determining whether the differences between treat-
ments are greater for particular groups of patients. However, any
such analyses should, ideally, be regarded as hypothesis-gener-
ating, for testing in future studies. If subgroup analyses are to be
performed, they need to be as complete as possible and should
preferably involve commonly defined subgroups and outcomes
across all ofthe trials in areview. This will rarely be possible ifthe
review is based solely on the published literature as, regardless of
the problems associated with not being able to include unpub-
lished trials, the information that has been published on various
subgroup analyses may well be incomplete and is probably biased.
Although trialists could be asked to fill in a table containing aggre-
gate data on different types of patient and of outcome, this might
prove difficult for many trialists, particularly for those with no
data management or statistical support. In addition, ifthe outcome
data had also to be supplied for different lengths offollow-up, the
necessary tables could potentially contain more cells than patients
in a trial. To complete such a table, the trialists would also need to
adopt the centrally determined definitions for subgroups and
outcomes. Thus, the collection of IPD may prove simpler for the
trialists. It also allows the secretariat to prepare the necessary files
for analysis and to apply consistent subgroup and outcome defini-
tions across the included trials.
For example, in acute leukaemia, it is usual to distinguish
between children and adults both in trials and in clinical practice
generally. However, the definition of a child varies between trial-
ists. Some trials in the USA have included patients up to 21 years
ofage (van Eys et al, 1989), whereas childhood trials in the UK are
often restricted to those aged 14 years and younger (Chessells et
al, 1995). A consequent advantage of an IPD meta-analysis is that
a common definition of such a patient characteristic can be used
across all the trials. This has recently been performed to investi-
gate the duration and intensity of therapy for childhood acute
lymphoblastic leukaemia (Childhood ALL Collaborative Group,
1996). It is also possible that the data collected for an IPD meta-
analysis could be used to investigate the effects of treatment if
varying definitions are used for a particular subgroup.
Leukaemia also provides a useful example of when there may
be a variety ofdefinitions for a particular outcome. This is so with
'event-free survival', in which the outcomes considered as
'events' may vary between trial groups. If the relevant data on
each possible contributing event are collected from each trial then
a common definition can be adopted (Childhood ALL
Collaborative Group, 1996). Again, the IPD meta-analysis might
also allow for the presentation of results from each of the
contributing events separately so that the reader of the review can
obtain an estimate of the relative effects of treatment on whatever
they define as 'event-free survival'.
Checking and correction of data
Although our combined experience is that fraud in trials appears to
be rare; errors, misunderstandings or inadvertently inappropriate
analyses are not and the ability to check the individual patient data
may reveal problems or misunderstandings that can be resolved
through consultation with the trialists. This can be particularly
important in the treatment of cancer as such trials tend to run over
relatively long periods of time and are, therefore, particularly
susceptible to design changes during their course. As an example,
it might be decided that one of the treatments in a two-arm trial
should be stopped and so allocations to that arm are closed even
though accrual may continue to the other treatment group. Only
the patients who were concurrently randomized in such a study
should be analysed for comparative purposes, but this is not
always done. If the individual patient data are available then this
can be rectified (Birch et al, 1988; Pignon et al, 1992). In addition,
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Table 1 Survival differences at fixed time points for 1283 patients in 11 trials
of platinum-based combination chemotherapy vs single non-platinum drugs
in advanced ovarian cancer (Stewart and Parmar, 1993)
Follow-up (years) Odds ratio Absolute improvement P-value
in survival (%)
1 0.87 3.2 0.23
2 0.76 6.2 0.02
3 0.88 2.3 0.31
4 0.92 1.2 0.56
5 0.94 0.8 0.69
checking ofthe raw data might reveal that a trial had used a quasi-
random method of allocation (e.g. alternation or odd/even birth
date) and, because of the danger that such schemes can lead to
bias, these trials might then be excluded from the meta-analysis.
Obtaining unpublished additional data
As already noted, death is often one of the most important
measures of outcome in cancer trials. In malignancies with very
poor prognosis, a large proportion of patients will die relatively
quickly and follow-up ofa few years may be sufficient to obtain a
reliable estimate of the relative efficacy of the treatments under
investigation. However, in some diseases (such as early-stage
breast orprostate cancer), many patients who will eventually die of
their disease might live several years beyond diagnosis and
primary treatment. It could then be many years or decades before a
reliable estimate ofthe mortality effects ofthe different treatments
can be made. This may be true for overall mortality, but it mightbe
especially true for cause-specific mortality (or for the incidence of
second cancers) ifthe treatments have long-term hazards.
IPD meta-analyses are a means by which this can be investi-
gated and may be the best way for some long-term effects to be
assessed. By periodically collecting updated data on each patient,
the amount offollow-up can be continually extended and ifthe end
point of interest is death this can sometimes be achieved through
the use ofnational mortality records, eitherby the trialists orby the
reviewer (Stewart and Clarke, 1995). Similarly, cancer registries
might be used to help collect data on the diagnosis of second
cancers. If a central database has already been prepared that
contains the necessary baseline variables for each patient, it is a
relatively easy task to add this type of additional follow-up
information, ifit is available, before conducting new analyses.
As an example of the importance of continuing to extend the
follow-up in a disease such as breast cancer, the collaborators in
the EBCTCG overview were, in 1990, sent a questionnaire asking
them to predict the 10-year survival rates, after having seen the 5-
year results in 1985 (EBCTCG, 1988). Of the 78 trialists who
responded, none predicted thatthe treatments given during the first
few years after diagnosis would produce additional benefits
between years 5 and 10 as great as those actually observed (Clarke
and Stewart, 1994).
As well as providing unexpected findings on overall mortality
during longer follow-up, an IPD meta-analysis might also allow
the investigation of cause-specific mortality (e.g. long-term fatal
side-effects). This can be particularly important in cancer when
long-term hazards are quite possible because of the biological
mechanisms of the treatments used. Although observational
studies may help to investigate these, systematic reviews of the
relevant randomized trials from far enough in the past will have
the substantial benefit ofthe removal ofsystematic bias. One such
investigation has been performed (Cuzick et al, 1994) for a subset
of the trials of radiotherapy after surgery for breast cancer, in
which detailed information on causes of death was sought. This
found an excess of cardiovascular deaths in the period more than
10 years after primary treatment for women allocated to receive
radiotherapy. These trials used old radiotherapy techniques so it is
unclear how directly applicable the findings are to modem tech-
niques. But, it was still important to find that radiotherapy can
produce such hazards and the individual trials were too small to
investigate this reliably.
DISCUSSION
The two ways ofcollecting large-scale randomized evidence: large
prospective randomized trials and systematic reviews ofpast trials
are complementary. Systematic reviews that contain IPD meta-
analyses might generate hypotheses about particular interventions
or subgroups for testing in future trials and they can also foster
international collaboration that might help to facilitate the conduct
of randomized trials that are sufficiently large to investigate reli-
ably any promising new treatments. For example, two large trials
were started (Le Pechoux et al, 1995; Stephens et al, 1996) after
the IPD meta-analysis of chemotherapy in non-small-cell lung
cancer (Non-Small Cell Lung Cancer Collaborative Group, 1995).
CONCLUSION
This report highlights the need for reviewers to consider whether
systematic reviews in cancer should involve updated and centrally
collected data on each and every randomized patient. An IPD
meta-analysis may require more time and resources than some
othertechniques for systematic review, but it should lead to a more
reliable assessment ofthe treatments under investigation.
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APPENDIX
IPD meta-analyses oftreatments or screening for cancer that have assessed remission, relapse or survival unless
otherwise stated (listed alphabetically by cancer site)
Cancer Review group Scope ofthe project Brief details ofthe project Contact address
Bladder Advanced Bladder Randomized trials of local IPD were soughtfrom all trials of neoadjuvant or ABCOC,
Cancer Overview therapy vs neoadjuvant or concurrent chemotherapy in locally advanced MRC CTO,
Collaboration (ABCOC) concurrent chemotherapy in bladder cancer. The main end point was survival, 5 Shaftesbury Road,
locally advanced bladder and subgroup analyses by age, sex, stage and Cambridge CB2 2BW,
cancer grade were performed. Results were published in 1995 UK
(Advanced BladderOverview Collaboration, 1995).
The meta-analysis will be updated during 1998/99.
Bladder EORTC and MRC Randomized trials of IPD are being collected and preliminary results of a EORTC,
combined analysis prophylactic treatment ofTaTl combined analysis ofthe EORTC and MRC trials Meta-analysis Unit,
bladder cancer has been published (Pawinski etal, 1996). Plans EORTC Data Center,
are being made to expand the meta-analysis to Avenue E Mounier 83,
include all relevant trials. Boite 11,
1200 Bruxelles,
Belgium
Breast Cuzick et al Randomized trials of IPD were collected in the eariy 1980s and the DrJack Cuzick,
radiotherapy vs none results on long-term survival, were published first in ICRF,
which began before 1975 and 1987 (Cuzick etal, 1987a and b). Furtherfollow-up PO Box 123,
of radical mastectomy vs and more detailed information, including Lincoln's Inn Field,
simple mastectomy with whetherthe tumourwas in the left orthe right breast London WC2A 3PX,
radiotherapy and the cause of death for women dying more than UK
10 years after primary treatment, were collected
and published subsequently forthe unconfounded
trials of radiotherapy (Cuzick etal, 1994).
Breast Eariy Breast Cancer Randomized trials ofany IPD were first soughtfortrials oftamoxifen or EBCTCG,
Trialists' Collaborative aspect of the treatment of early chemotherapy vs control in 1984 (Anon, CTSU,
Group (EBCTCG) (i.e. operable) breast cancer, 1984). The results ofthese treatments on 5-year Radcliffe Infirmary,
which had survival as the survival were published in brief (EBCTCG, 1988), Oxford OX2 6HE,
primary end point and as a monograph containing additional UK
information (EBCTCG, 1990). Furtherfollow-up,
and data from all othertrials that had assessed
treatments foreariy breast cancerwere collected
in 1989/90 and the new analyses have been
published (EBCTCG, 1992 and 1995). A third cycle
was initiated, and the preliminary analyses were
presented to thetrialists, in 1995. The results for
the ovarian ablation trials have been published
(EBCTCG, 1996), and other papers have been
submitted. The overview takes place every 5
years and the fourth cycle will begin in 1999 fora
meeting oftrialists in 2000.
Breast Perioperative Randomized trials of IPD have been collected on both perioperative EORTC,
chemotherapy trialists perioperative chemotherapy in monochemotherapy and polychemotherapy. An Meta-analysis Unit
early breast cancer abstract reporting the results of a meta-analysis of (address as above)
the latter was published in 1995 (Clahsen et al,
1995) and a manuscript has been accepted for
publication (Clahsen et al, 1998).
Breast Nystrom et al Randomized trials of Seven randomized trials of mammographic Dr Lennarth Nystrom,
mammographic screening screening have been identified, but only four of Department of
these evaluated mammography alone and all these Epidemiology
were performed in Sweden. In 1987, an IPD meta-analysis and Public Health,
was initiated to compare women who Umea University,
were invited for screening with those who were not S-901-85 Umea,
invited, using breast cancer mortality as the Sweden
end point. Results from the firstfollow-up were
published in 1993 (Nystrom et al, 1993). Further
follow-up was collected and an updated report
has been published (Larsson et al, 1997).
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Cancer Review group Scope ofthe project Brief details ofthe project Contact address
Breast EORTC
Colorectal Liver Infusion
Meta-analysis Group
Colorectal Colorectal Cancer
Collaboration
Colorectal,
advanced
MAGIC, FUFOL
Colorectal, MAGIC, FUMTX
advanced
Colorectal, MAGIC, MAIA
advanced
Colorectal,
advanced
MAGIC/IGR, FUCONT
Glioma Ongoing
Head and Meta-analysis of
neck Chemotherapy in Head
and Neck Cancer
Collaborative Group
(MACH-NC-CG)
Randomized trials of LHRH-
agonist and tamoxifen
treatment of metastatic breast
cancer
Randomized trials of
continuous, post-operative
portal vein infusion of
chemotherapy lasting some
days vs control
Randomized trials of any
aspect of the primary or
adjuvant treatment of any type
of colon or rectal cancer in
which there might be some
hope of cure
Randomized trials of 5-FU
alone vs 5-FU + folinic acid
Randomized trials of 5-FU
alone vs 5-FU +
methotrexate
Randomized trials of
intravenous 5-FU or FUDR
vs hepatic artery infusion
5-FU
Randomized trials of 5-FU
bolus vs 5-FU continuous
infusion
Randomized trials of
chemotherapy
Randomized trials of chemo-
therapy vs none in squamous
cell carcinoma receiving
locoregional treatment, of
chemotherapy and organ
preservation(Pignon et al, 1995),
and ofdifferenttimings ofthe
same radiochemotherapy
combinations
The protocol forthis project is currently being
finalized.
IPD were collected fortrials beginning before 1987
and the results were published in 1997 (Liver
Infusion Meta-analysis Group, 1997).
IPD were collected fortrials beginning before 1987
and the preliminary analyses were presented tothe
trialists in 1993. Additional data have since been
collected, before the preparation of the
appropriate manuscripts.
A protocol was sent to all investigators in October
1990. IPD were collected from December 1990 to
April 1991 and preliminary analyses were
presented to trialists in May 1991. A manuscript
was circulated among trialists laterthat year and
was published in 1992 (Advanced Colorectal
Cancer Meta-analysis Project, 1992).
A protocol was sent to all investigators in October
1991. IPD were collected from December 1991 to
April 1993 and preliminary analyses were
presented to trialists in May 1993. A manuscript
was circulated among trialists laterthat year and
was published in 1994 (Advanced Colorectal
Cancer Meta-analysis Project, 1994).
A protocol was sent to all investigators in October
1993. IPD were collected from December 1993 to
December 1994 and preliminary analyses were
presented to trialists in May 1995. A manuscript
was circulated among trialists later that year and
was published in 1996 (Meta-analysis Group in
Cancer, 1996). A pharmacoeconomic study is
ongoing.
A protocol was sent to all investigators in August
1994. IPD were collected from November 1994 to
April 1996 and preliminary analyses were
presented to trialists in May 1996. A manuscript is
in preparation.
A protocol forthis project was circulated to tialists
in June 1997.
IPD were collected fortrials that
started after 1965 and were completed before 1994.
The main end point is survival. Subgroup analyses
by age, sex, performance status, site of primary
tumourand stage are planned. Preliminary results
werepresented to trialists in January 1997 and a
manuscript will be submitted in 1997. A second
cycle of the meta-analysis is planned.
EORTC,
Meta-analysis Unit
(address as above)
Meta-Analysis Group
in Cancer (MAGIC),
Department ofOncology,
H6pital Henri Mondor,
51 av du Marechal de
Lattre de Tassigny,
94000 Creteil, France,
and
Colorectal Cancer
Collaboration,
CTSU
(address as above)
Colorectal Cancer
Collaboration,
CTSU
(address as above)
Meta-Analysis Group
in Cancer (MAGIC)
(address as above)
Meta-Analysis Group
in Cancer (MAGIC)
(address as above)
Meta-Analysis Group
in Cancer (MAGIC)
(address as above)
Meta-Analysis Group
in Cancer (MAGIC)
(address as above)
and
DrJean-Pierre Pignon,
Department of
Biostatistics,
Institut Gustave-
Roussy- IGR,
rue Camille Desmoulins,
94805 Villejuif Cedex,
France
Meta-analysis Group
MRC CTO
(address asabove)
DrJean-Pierre Pignon
(address as above)
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Head and Currently in design
neck
Hodgkin's Intemational Hodgkin's
disease Disease Collaborative
Group
Hodgkin's International Database
disease on Hodgkin's Disease
Overview Study Group
Leukaemia,
acute
lympho-
blastic (ALL)
Childhood ALL
Collaborative Group
Leukaemia, AML Collaborative
acute Group (AMLCG)
myeloid
(AML)
Leukaemia,
acute
myeloid
(AML)
Leukaemia,
chronic
lymphocytic
(CLL)
Leukaemia,
chronic
myeloid
(CML)
AML Collaborative
Group (AMLCG)
CLL Trialists'
Collaborative Group
CMLTrialists'
Collaborative Group
Lung, non- Non-Small Cell Lung
small-cell CancerCollaborative
Group
Randomized trials comparing
conventional radiotherapy to
modified radiotherapy
fractionation in squamous cell
carcinoma
Randomized trials assessing
eitherchemotherapy after
radiotherapy, orthe extent of
radiotherapy foreariy-stage
Hodgkin's disease
Randomized trials of combined
modality treatment vs
chemotherapy alone for
intermediate- or advanced-stage
Hodgkin's disease
Randomized trials ofvarious
aspects of the treatment of
childhood ALL
Randomized trials ofvarious
aspects of the treatment of AML
Randomized trials of
autologous bone marrow
transplantation (A-BMT) vs
control orchemotherapy
Randomized trials ofvarious
aspects ofthe treatment of
CLL
Randomized trials of various
aspects of the treatment of
CML
Randomized trials of
chemotherapy
This meta-analysis is currently at the planning
stage, with discussion taking place between the
IGR Biostatistics Department and the EORTC
Meta-analysis Unit. It will be coordinated on behalf
of an intemational collaborative group, and IPD will
be soughtfrom all relevanttrials.
Aggregate data were collected in 1990 and a draft
report was circulated to trialists (Specht et
al, 1991). It was agreed that this should not be
submitted until the analyses had been improved by
the use of IPD. These were collected (Specht
and Gray, 1996) and the results have been
published (IntemationalHodgkin's Disease
Collaborative Group, 1998).
IPD have been collected since 1993 and the
results have been published
(Loeffler et al, 1998).
IPD were collected from trials assessing different
durations of maintenance therapy, and preliminary
analysis was presented to thetrialists in 1991. IPD
were subsequently collected for otheraspects of
maintenance or intensification therapy, and the
results ofthese analyses have been published
(Childhood ALL Collaborative Group, 1996). This
overview has also led to the production of a
uniquely comprehensive annual register of ongoing
randomized trials in the treatment of this disease
(Sinclair et al, 1995). The nextcycle of the
overview will concentrate on CNS-directed
therapies and anthracyclines. Data collection will
begin in 1998.
IPD were collected fortrials comparing different
anthracyclines orassessing different doses of cytosine
arabinoside in 1994. Preliminary results have been
presented forthe former (Wheatley et al, 1995) and a full
manuscript has been submitted. Further data
were collected forthe latter, along with IPD for
trials assessing growth factor support,
the intensification oftherapy, orthe duration of
maintenance and were presented to the AMLCG in
1996. The next cycle of the overview will
concentrate mainly on growth factors and
preliminary analyses will be presented in 1998.
IPD have been collected and preliminary analyses
were presented to the AMLCG in 1995 and 1996.
IPD were collected from trials comparingeariy
vs deferred treatment, the addition of
prednisone, or CHOP therapy vs other
chemotherapy and preliminary analyses were
presented to thetrialists in 1993. Furtherfollow-up
information has been collected and a manuscript
will besubmitted in 1998.
IPD were collected from trials assessing the use of
interferon, orcomparing hydroxyurea vs
busulphan, and preliminary analyses were
presented in 1995; the results have been
published (Chronic Myeloid LeukemiaTrialists'
Collaborative Group, 1997).
IPD were sought from all trials that started after
1965 and were completed before 1992. The main
end point was survival and subgroup analyses by
age, sex, stage, histology and performance status
DrJean-Pierre Pignon
(address as above)
and
EORTC
Meta-analysis Unit
(address as above)
Dr Lena Specht,
Department of Oncology,
Heriev Hospital,
DK-2730 Herlev,
Denmark
Dr Markus Loeffler,
IMISE,
University of Leipzig,
D-04103 Leipzig,
Germany
Childhood ALL
Collaborative Group
CTSU
(address as above)
AMLCG
CTSU
(address as above)
EORTC
Meta-analysis Unit
(address as above)
and AMLCG
CTSU
(address as above)
CLL Trialists'
Collaborative Group
CTSU
(address as above)
CMLTrialists'
Collaborative Group
CTSU
(address as above)
NSCLCG
MRC CTO
(address as above)
and
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Lung, non- PORT Collaborative
small-cell Group
Lung, Small Cell Lung Cancer
small-cell Meta-Analysis Group
Lung, Prophylactic Cranial
small-cell Irradiation Overview
Collaborative Group
(PCIO-CG)
Melanoma MAGIC/EORTC
Multiple Myeloma Trialists'
myeloma Collaborative Group
Non-
Hodgkin's
lymphoma
Non-
Hodgkin's
lymphoma
Ongoing
EORTC
Oesophageal Oesophageal Cancer
Collaborative Group
(OCCG)
Randomized trials of
post-operative radiotherapy
Randomized trials ofthoracic
radiotherapy vs none in
limited stage small-cell lung
cancertreated by
chemotherapy
Randomized trials of
prophylactic cranial irradiation
vs none, in complete
responders (Arriagada et al,
1997)
Randomized trials of any
adjuvant treatment of any type of
malignant melanoma
Randomized trials of any
aspect of the treatment of
multiple myeloma
Randomized trials of interferon
Randomized trials of regimens
containing either doxorubicin or
mitoxantrone
Randomized trials of
preoperative radiotherapy in
oesophageal cancer
were performed. Results were presented to trialists in
1993 and published in 1995 (Non-Small Cell Lung
Cancer Collaborative Group, 1995). The
meta-analysis will be updated during 1998/99.
This project was initiated in 1996. IPD have been
requested from all trials that started after 1965 and were
completed before 1996. The main end points are survival
and progression-free survival. Subgroup analyses by age,
sex, stage, histology and performance status were carried
out. Results were presented to trialists in August 1997.
A manuscript will be published in 1998.
IPD were collected fortrials beginning before 1989.
The main end pointwas survival and subgroup
analyses by age, sex and performance status were
performed. Results were presented to trialists in
1991 and published in 1992 (Pignon et al, 1992).
New data including furtherfollow-up are being collected.
IPD are being collected fortrials beginning before
1996. The main end point is survival. The
secondary end points are disease-free survival,
time to brain metastases, time to other metastases
and time to locoregional recurrence. Subgroup
analyses by age, sex, performance status,
treatment use to obtain complete response and
extension of initial disease are planned.
Preliminary results were presented to trialists in
August 1997.
A protocol was sent to all investigators in May
1995. IPD are being collected.
IPD were collected in 1993 (Clarke et al, 1992) and
preliminary analyses have been presented to the
trialists. A manuscript has been submitted forthe
comparison of combination chemotherapy vs melphalan
and prednisone. Further IPD are being collected for
trials of interferon vs control and preliminary results were
presented to the relevant trialists in 1997. In addition, the
IPD (from neariy 13000 patients) might be used to develop
a new prognostic staging system.
A protocol has been prepared and data are being
collected.
A summary ofthe protocol has been sent to all
collaborators and the protocol itself is now being
prepared.
IPD were sought from all trials that were
completed by 1994. The main end-point was
survival and subgroup analyses were performed by age,
sex and tumour location. The results were
presented totrialists in 1995 and updated in 1996.
A paper has been submitted for publication.
DrJean-Pierre Pignon
(address as above)
PORT
MRC CTO
(address as above)
DrJean-Pierre Pignon
(address as above)
DrJean-Pierre Pignon
(address as above)
Meta-Analysis Group
in Cancer (MAGIC)
(address as above)
and
EORTC Meta-analysis
Unit (address as
above)
MyelomaTrialists'
Collaborative Group
CTSU
(address as above)
DrAma Rohatinerand
DrWalter Gregory,
Medical Oncology,
St Bartholomew's
Hospital,
45 Little Britain,
West Smithfield,
London EClA 7BE,
UK
EORTC
Meta-analysis Unit
(address as above)
and
Dr Magnus Bjorkholm
and Dr Eva Osby,
Department of Medicine,
Karolinska Hospital,
Stockholm,
Sweden
OCCG
MRC CTO
(address as above)
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Ovarian Advanced Ovarian
CancerTrialists' Group
(AOCTG)
Ovarian Ovarian cancer
meta-analysis
analysis project
Ovarian Currently in design
Prostate Prostate Cancer
Trialists' Collaborative
Group (PCTCG)
Randomized trials of
chemotherapy in advanced
ovarian cancer comparing
single-agent vs
combination non-platinum
therapies, single non-platinum
vs platinum combinations,
non-platinum combinations
vs the same combination
plus platinum, single vs
combination platinum, or
cisplatin vs carboplatin
Randomized trials comparing
cyclophosphamide plus
cisplatin vs the same plus
doxorubicin
Randomized trials of paclitaxel
Randomized trials of any
aspect of the treatment of
prostate cancer
Soft tissue Sarcoma Meta-analysis Randomized trials of adjuvant
sarcoma Collaboration chemotherapy
Solid and MAGIC Randomized trials of any
non-solid chemotherapy vs the same
tumours plus G-CSF
Uterine
cervix
Currently in design Randomized trials of
neoadjuvant chemotherapy
IPD were sought from all relevanttrials of
chemotherapy in advanced ovarian cancer.
Results were presented totrialists in 1990 and
published in 1991 (Advanced Ovarian Cancer
Trialists Group, 1991). Further data were collected
in 1995, and updated analyses forall butthe first
comparison were performed. These included
subgroup analyses of age, stage, performance
status, extent ofoperation, residual tumour bulk,
histological cell type and grade forthe cisplatin
vs carboplatin trials. A manuscript has been
submitted for publication. An associated project
investigating dose intensity in cisplatin vs
carboplatin trials is ongoing.
Results were published in 1991 (Ovarian Cancer
Meta-analysis Project, 1991).
This meta-analysis is currently in design but IPD
will be sought forall relevant trials. The primary
end point will be survival though a limited amount of
quality-of-life data may also be collected.
IPD were collected from trials assessing maximum
androgen blockade in advanced prostate cancer
and the results have been published (Prostate
CancerTrialists' Collaborative Group, 1995). The
project has been extended to all randomized trials
and preliminary analyses were presented to the
trialists in 1997.
IPD were soughtfrom all trials that started after
1970. The principal end point was survival with
local recurrence-free interval, distant
recurrence-free interval, recurrence-free interval
and recurrence-free survival as additional
end points. Subgroup analyses were performed by age,
sex, disease site, histology, grade, tumoursize,
primary therapy and extent of resection. Results
were presented to collaborators in 1995 and at
ASCO in 1996 (Tiemey et al, 1996). These were
updated in 1996 and a manuscript has been
submitted for publication.
A protocol was sent to all investigators in
December 1994. IPD are being collected.
This meta-analysis is currently at the planning
stage, with discussions taking place between the
MRC Meta-analysis Group and the EORTC Meta-analysis
Unit. It will be coordinated on behalf
of an intemational collaborative group, and IPD will
be sought from all relevanttrials.
AOCTG
MRC CTO
(address as above)
Meta-Analysis Group
in Cancer (MAGIC)
(address as above)
Meta-analysis Group
MRC CTO
(address as above)
PCTCG,
Biometrics Department,
Netherlands Cancer
Institute,
Plesmanlaan 121,
1066 CX Amsterdam,
The Netherlands
Meta-analysis Group
MRC CTO
(address as above)
Meta-Analysis Group
in Cancer (MAGIC)
(address as above)
Meta-analysis Group
MRC CTO
(address as above)
and
EORTC
Meta-analysis Unit
(address as above)
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